Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Has Consensus Target Price of $41.80 According to Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $41.60.

Several equities research analysts recently issued reports on SNDX shares. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Mizuho set a $43.00 target price on Syndax Pharmaceuticals in a research note on Tuesday. JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th.

Insider Activity at Syndax Pharmaceuticals

In related news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the transaction, the director directly owned 239,763 shares in the company, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Syndax Pharmaceuticals during the second quarter valued at approximately $197,177,000. Bank of America Corp DE purchased a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $88,426,000. Elmind Capital LP purchased a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $40,550,300. Trails Edge Capital Partners LP purchased a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $24,264,600. Finally, Bank of New York Mellon Corp bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $22,736,000.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $9.54 on Tuesday. The company’s 50 day simple moving average is $16.33 and its two-hundred day simple moving average is $20.02. The company has a debt-to-equity ratio of 38.95, a current ratio of 4.69 and a quick ratio of 6.44. Syndax Pharmaceuticals has a 1 year low of $9.22 and a 1 year high of $25.59. The stock has a market capitalization of $858.87 million, a PE ratio of -4.04 and a beta of 0.48.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). The firm had revenue of $83.30 million for the quarter, compared to analysts’ expectations of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The firm’s revenue for the quarter was up 81.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.70) earnings per share. Analysts predict that Syndax Pharmaceuticals will post -2.09 earnings per share for the current fiscal year.

Key Stories Impacting Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax expects 19 drug abstracts to be featured at ASH 2026, which may raise visibility for its oncology pipeline. The headlines do not disclose the data or establish whether the findings are favorable, so the abstracts are a potential catalyst rather than confirmed positive results. Article: Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts Article: Why Is Syndax Pharmaceuticals Drawing So Much ASH 2026 Attention?
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $36 price target. Its revisions were mixed: it slightly improved some 2026 and longer-term estimates, but reduced its 2027 and 2028 forecasts. Analyst estimates and rating
• Neutral Sentiment: A Seeking Alpha analysis says Revuforj is showing strong commercial growth, but identifies potential frontline AML use as a key factor for the company’s outlook. Article: Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Syndax investors. The announcement does not provide details of the claims, but the investigation adds legal uncertainty and may weigh on sentiment. Article: Pomerantz Law Firm Investigates Claims On Behalf of Syndax Investors

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.